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Salts of the chelating agent edathamil (ethyl-
enediaminetetraaeetie acid, or EDTA) may
cause toxic effects with repeated intravenous
administration. Seven', reviewing this problem,
stressed the reports of renal tubular damage.
Dudley and co-workers2 described severe hydropic
degeneration of the proximal convoluted tubules
of the kidney in two patients who died after
receiving repeated large intravenous doses of
edathamil disodium for the treatment of hyper-
caleemia associated with vitamin D intoxication
and osteolytie metastatic carcinoma. Neeropsy
in these cases revealed engorgement of the
retieuloendothelial cells of the liver, spleen, bone
marrow and lymph nodes, with sharply defined,
coarse, eosinophilie granules that had the staining
characteristics of mueoprotein or glycoprotein.
Foreman and associates' studied the nephro-
toxicity of edathamil calcium-disodium in rats,
noting that repeated intraperitoneal injection of
moderate doses of the drug produced hydropic
degeneration of the proximal convoluted renal
tubules. Development of lesions and their severity
depended on both the daily dose and the number
of days of administration. They calculated that
histologic evidence of renal lesions would develop
in 50 per cent of the animals with a dose of 203
mg. per kilogram of body weight per day for 16
days, and they estimated that 95 per cent of the
animals probably would have lesions with doses
ranging between 131 and 314 mg./kg./day for
16 days. These authors stated that no other
tissues of the body appeared to be affected and
the lesions produced in the kidney were readily
reversible on withdrawal of the drug. Foreman's
group suggested that edathamil ealeium-disodium
should be used in man in doses of approximately
50 mg/kg/day and be given for 5 days, fol-
lowed by 2 days of rest before the regimen was
repeated.
At the Mayo Clinic, we have used chelation
with the disodium salt of edathamil for the treat-
ment of scieroderma for the past 4 years. Even
when this agent is administered according to a
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treatment schedule adhering closely to that
suggested by Foreman and co-workers, we have
noted occasional evidence of renal irritation,
manifested on routine urinalysis by the appear-
ance of erythroeytes, casts and protein. A few
patients also experienced systemic reactions, with
headache, malaise, chills and fever, and increased
urinary frequency without dysuria. Occasionally,
the value for blood urea increased during these
episodes of toxicity. No evidence of infection in
the urinary passages or elsewhere has been found.
In an attempt to evaluate this renal irritation
with edathamil disodium, it was noted that the
onset of renal symptoms occasionally appeared
to coincide with the use of procaine or ehlor-
promazine as supportive therapy in conjunction
with edathamil chelation.
On the basis of these clinical observations, plus
the fact that both procaine and chlorpromazine
on hydrolysis may exhibit metal-binding prop-
erties4, it was decided to investigate the possible
enhancement by these drugs of the renal toxicity
produced by edathamil disodium in animals.
MATERIAL AND METHOD
Male albino rats weighing approximately 300
to 400 gm. each were used. The rats were kept in
individual cages after insertion of an indwelling
intraperitoneal catheter. All drugs used were
diluted to a volume of 10 ml. with a 0.9 per cent
solution of sodium chloride and were administered
through the intraperitoneal tube over a 4-hour
period by use of a timed automatic injection ap-
paratus.
Four groups of 10 rats each were used. Each
animal received daily consecutive infusions for a
varying period up to 15 days. Group 1 received
edathamil disodium in a dose of 300 mg./kg./day.
Group 2 received the same dose of edathamil
disodium plus 10 mg. of procaine per day. Group 3
received the same dose of edathamil disodium
plus 0.5 mg. of chlorpromazine per day. Group 4
received edathamil disodium in a dose of 600
mg./kg./day.
Rats from each group were killed at regular
intervals during the course of the study (4, 8, 10,
12 and 15 days, respectively), and specimens were
taken from the kidneys, liver and spleen for his-
tologic examination. Control groups of rats re-
ceived daily intraperitoneal injections of procaine
alone (10 mg.) or chlorpromazine alone (0.5 mg.)
for 15 consecutive days, after which the animals
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FIG. 1. a. Kidney from rat given edathamil disodium in a dose of 300 mg./kg./day for 15 days. Note
the severe hydropic degeneration of the proximal convoluted tubules, with complete destruction of
tubular epithelium in some zones (hematoxylin and eosin; X140). 5. Kidney from rat given edathamil
disodium in a dose of 600 mg./kg./day for 5 days. The cells of the proximal convoluted tubules show
pronounced cytoplasmic vacuolization and some pyknotic nuclei (hematoxylin and eosin; X300). c.
Normal rat kidney for comparison (hematoxylin and eosin; X300).
were killed and specimens were taken for his- developed in all the rats treated with the 300-mg.
tologic examination, dose of edathamil disodium. The first signs of
this damage appeared about 12 days after initia-
RESULTS . . .tion of the treatment, with definite evidence of
These studies confirmed the renal toxicity of renal tubular lesions in nll animals treated for
edathamil disodium. Renal tubular damage 15 consecutive days.
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Histologic examination of the kidneys revealed
patchy involvement of the epithelium of the
proximal convoluted tubules, with severe
hydropic degeneration. Changes in the tubular
epithelial cells varied from small irregular cyto-
plasmic vacuoles unassociated with nuclear
changes to cells showing single large cytoplasmic
vacuoles with associated pyknotic nuclei. In
some zones, the tubular epithelium was com-
pletely destroyed (fig. la). The glomeruli and
distal tubules remained unaltered. Inflammatory
changes were absent. Other tissues did not exhibit
significant changes in any of the groups of animals
studied. Eosinophilic granules in reticuloendo-
thelial cells, as reported by Dudley and
associates2, were not found in any of the tissues
examined.
In those rats receiving edathamil disodium in
a dose of 600 mg/kg/day, renal lesions developed
after only 4 or 5 days of administration of the
drug. These changes were histologically similar in
nature to and were no more severe than those
developing in rats given the 300-mg. dose for
longer periods (fig. 15). A section of normal rat
kidney is included for comparison (fig. lc).
However, the animals receiving the 600-mg.
dose became moribund after 4 or 5 days and
failed to survive longer than 6 days.
A number of rats died at night during the
course of this study, and tissues for histologic
examination were not taken from them. Although
values for serum calcium were not determined at
the time of death, we attributed the death of
these animals to the toxic effects of sequestration
of calcium, which is known to occur with large
doses of edathamil disodium. The levels of serum
calcium in moribund rats were slightly lower than
normal. However, when large doses of edathamil
disodium were given to rats over short periods in
preliminary studies, the quantity of calcium in
the serum was drastically reduced.
The renal lesions did not develop any more
rapidly or more severely in animals treated with
edathamil disodium plus procaine or ehlorpro-
mazinc than they did in rats treated with eda-
thamil disodium alone. Evidently, neither pro-
caine nor ehlorpromazine significantly poten-
tiated the renal toxicity of edathamil disodium
in the doses used in this study.
COMMENT
Salts of edathamil are not metabolized or
conjugated in the body5, and the reactions of
edathamil are probably caused by chelation of
metal. Foreman and co-workers3 suggested that
renal lesions caused by the administration of
edathamil ealcium-disodium may be a imini-
festation of the depletion of a metal essential to
some renal enzymatic system. This would lead to
accumulation of metabolites with increased
osmotic pressure in the tubular cells and imbibi-
tion of water, producing hydropic degeneration.
The lesions produced with edathamil disodium
are similar to those seen in nephrosis produced by
the administration of sucrose or by depletion of
potassium. If this metal-depletion hypothesis is
valid, it may be wise to limit the use of other
drugs with metal-binding properties in patients
receiving edathamil. However, procaine and
chlorpromazine, the two drugs that we suspected
might potcntiate renal irritation with edathamil,
and which have some metal-binding properties,
did not appear to enhance renal toxicity in the
rat.
In observing patients receiving edathamil, we
have noted that renal irritation may occur at
any time after the first few days of treatment.
This irritation is usually reversible with 1 or 2
days of rest, after which treatment may be
resumed cautiously. We have found that doses of
edathamil disodium in the range of 2 to 2.5 gm.
per day, administered for 5 days with 2-day rest
periods between courses, provide the most satis-
factory schedule of treatment.
Dehydration also may be a factor in the
production of renal lesions, since signs of irrita-
tion are noted more commonly in warm weather
and when patients tend to become dehydrated.
We encourage patients who are taking edathamil
disodium to maintain an adequate intake of
fluids.
SUMMARY
The major toxic effect of repeated parentcral
administration of the chelating agent cdathamil
disodium in humans and animals is the production
of hydropie degeneration of the proximal con-
voluted tubules of the kidney.
The appearance of these lesions depends on
both the daily dose of the drug and the number
of days it is given.
Although clinical observations suggested that
the simultaneous usc of procaine or ehlorpro-
mazine might enhance the renal toxicity of
edathamil disodium, studies in rats failed to
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reveal any potentiation of this toxicity by these
drugs.
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